# The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

> **NCT04670107** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 30 (actual)

## Conditions studied

- NSCLC
- Angiogenesis
- Immunotherapy

## Interventions

- **DRUG:** Anlotinib in combination with Immune checkpoint inhibitors

## Key facts

- **NCT ID:** NCT04670107
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04670107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04670107, "The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04670107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*